enGene to File Detalimogene BLA in 2H 2026, Slashes Workforce by 50% to Extend Runway
ENGN sits 18% above its 52-week low of $1.4 on light trading volume (0.3× avg).
Summary
enGene Therapeutics reported Q2 2026 financial results with $285 million in cash, cash equivalents, and marketable securities. The company announced plans to initiate a Biologics License Application (BLA) filing for its lead asset, detalimogene, in the second half of 2026, following 12-month complete response data and FDA engagement. To preserve capital and streamline operations, enGene also implemented a significant 50% workforce reduction, focusing resources on the BLA and precommercial activities. This update follows the company's announcement of updated interim Phase 2 LEGEND trial results in May and a recent name change. The current cash position of $285 million is a decrease from the $312.5 million reported in the last 10-Q. The planned BLA filing is a critical regulatory milestone for detalimogene, moving it closer to potential commercialization for high-risk bladder cancer. The substantial workforce reduction, while impacting employees, is a strategic move to extend the company's cash runway and focus on this key asset, which is often viewed favorably by investors in clinical-stage biotech companies. The company expects to engage with the FDA and release 12-month complete response data from the LEGEND pivotal cohort in the second half of 2026, preceding the BLA filing.
At the time of this announcement, ENGN was trading at $1.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $108.5M. The 52-week trading range was $1.40 to $12.25. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.